<DOC>
	<DOCNO>NCT01713400</DOCNO>
	<brief_summary>To determine whether treatment ustekinumab alter ratio T Regulatory Cell ( Treg ) /total cluster differentiation 4 ( CD4 ) + cell peripheral blood day 30 post-hematopoietic cell transplantation ( HCT ) .</brief_summary>
	<brief_title>Tacrolimus , Sirolimus Ustekinumab vs. Tacrolimus Sirolimus Prevention Acute Graft-Versus-Host Disease</brief_title>
	<detailed_description>This comparative study ass biologic clinical activity agent ustekinumab give concert establish regimen SIR/TAC . Patients randomly assign standard regimen tacrolimus/sirolimus ( TAC/SIR + placebo ) vs. investigational regimen tacrolimus/sirolimus/ustekinumab ( TAC/SIR/U ) 1:1 scheme .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Hematologic disorder require allogeneic hematopoietic cell transplantation Adequate vital organ function : Left ventricular ejection fraction ( LVEF ) &gt; /= 45 % multigated acquisition ( MUGA ) scan FEV1 , FVC , diffuse lung capacity oxygenation ( DLCO ) &gt; /= 50 % predict value pulmonary function test Transaminases ( AST , ALT ) &lt; 3 time upper limit normal value Creatinine clearance &gt; /= 50 cc/min . Performance status : Karnofsky Performance Status Score &gt; /= 60 % . Active infection control appropriate antimicrobial therapy HIV , hepatitis B , hepatitis C infection Sorror 's comorbidity factor total score &gt; 3 Important modification comorbidity index calculation : DLCO include assessment pulmonary risk , except DLCO &lt; 50 % , merit score 3 thereby exclude trial . Antithymocyte globulin ( ATG ) part condition regimen Cyclophosphamide part conditioning regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Acute Graft v . Host Disease ( aGVHD )</keyword>
	<keyword>Graft v . Host Disease ( GVHD )</keyword>
</DOC>